Startup | October 15, 2021
AUM Biosciences closes US $ 27 million `Series A’ funding round
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The collaboration will support Canada with direct access to rapid pandemic response capabilities
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Subscribe To Our Newsletter & Stay Updated
